Clinical trials
Lung Diseases, Interstitial trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 6 |
| Completed | 6 |
| Recruiting | 5 |
| Unknown status | 3 |
| Terminated | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 7 |
| Bristol-Myers Squibb | 2 |
| GlaxoSmithKline | 2 |
| United Therapeutics | 2 |
| AstraZeneca | 1 |
| Coordinación de Investigación en Salud, Mexico | 1 |
| Gilead Sciences | 1 |
| Insmed Incorporated | 1 |
| Kyntra Bio | 1 |
| National Institute of Respiratory Diseases, Mexico | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases, Interstitial | 23 |
| Idiopathic Pulmonary Fibrosis | 6 |
| Scleroderma, Diffuse | 5 |
| Scleroderma, Systemic | 4 |
| Autoimmune Diseases | 3 |
| Pulmonary Fibrosis | 3 |
| Arthritis, Rheumatoid | 2 |
| Connective Tissue Diseases | 2 |
| Fibrosis | 2 |
| Hypertension, Pulmonary | 2 |
Trials
Showing 76 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.